Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $53.00.

A number of research analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Robert W. Baird cut their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Guggenheim restated a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently bought and sold shares of DNTH. Millennium Management LLC lifted its stake in shares of Dianthus Therapeutics by 160.2% in the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock valued at $1,972,000 after purchasing an additional 55,682 shares during the period. Northern Trust Corp increased its holdings in Dianthus Therapeutics by 21.2% in the fourth quarter. Northern Trust Corp now owns 245,523 shares of the company’s stock valued at $5,352,000 after buying an additional 42,923 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Dianthus Therapeutics by 13.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock worth $25,283,000 after acquiring an additional 136,633 shares during the period. Vestal Point Capital LP boosted its stake in shares of Dianthus Therapeutics by 172.2% during the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after acquiring an additional 680,000 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Dianthus Therapeutics by 0.8% during the 4th quarter. FMR LLC now owns 4,439,281 shares of the company’s stock worth $96,776,000 after acquiring an additional 36,133 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 1.0%

NASDAQ:DNTH opened at $17.44 on Friday. Dianthus Therapeutics has a twelve month low of $13.37 and a twelve month high of $32.27. The company has a market cap of $560.87 million, a PE ratio of -6.06 and a beta of 1.36. The company’s 50 day moving average is $19.27 and its two-hundred day moving average is $20.93.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.04. The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,544.23% and a negative return on equity of 29.26%. As a group, analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.